 Home > Active Ingredient News > Antitumor Therapy > Cancers: Survival benefits of EGFR/ALK-negative advanced NSCLC patients after first-line immunotherapy is approved: data from real-world studies

Cancers: Survival benefits of EGFR/ALK-negative advanced NSCLC patients after first-line immunotherapy is approved: data from real-world studies

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

mao inhibitors natural

plants cure cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

It is still challenging to select suitable patients for immune checkpoint inhibitor (ICI) treatment among non-small cell lung cancer ( NSCLC ) patients .
Recently, a team from Denmark conducted a real-world study to compare the overall survival (OS) of patients with EGFR/ALK-negative advanced NSCLC before and after the implementation of ICIs, and to determine the factors that affect the prognosis of OS .
The results were published in Cancers magazine .

It is still challenging to select suitable patients for immune checkpoint inhibitor (ICI) treatment among non-small cell lung cancer ( NSCLC ) patients .

Recently, a team from Denmark conducted a real-world study to compare the overall survival (OS) of patients with EGFR/ALK-negative advanced NSCLC before and after the implementation of ICIs, and to determine the factors that affect the prognosis of OS .
The results were published in Cancers magazine .
NSCLC immunity

The study screened the Danish Lung Cancer Database (DLCR) from January 1, 2013 to October 1, 2018 for advanced NSCLC for first-line treatment
.

According to the immune checkpoint inhibitors (ICI) before and after the approved treatment, they were divided into the pre-approved cohort (n=1658) and the post-approved cohort (n= 2055).
The latter was divided into the DLCR-CTx (chemotherapy) group (n= 1573) and the DLCR-ICI group (n=482)

The study screened the Danish Lung Cancer Database (DLCR) from January 1, 2013 to October 1, 2018 for advanced NSCLC for first-line treatment

Compared with the pre-approved cohort, the proportion of women in the post-approved cohort (50.

Compared with the pre-approved queue, the OS of the post-approved queue is significantly improved

Because the patient's PS, metastasis site, and anti-tumor treatment details in the DLCR database are lacking, the investigator included the relevant patient data in the EHRs database (n=579)
.

The median OS was 18.

Because the patient's PS, metastasis site, and anti-tumor treatment details in the DLCR database are lacking, the investigator included the relevant patient data in the EHRs database (n=579)

In the multivariate Cox regression analysis, PS=1 (HR = 1.

Subgroup analysis

Subgroup analyzes Subgroup analyzes

In summary, studies have shown that the approval of Immune Checkpoint Inhibitors (ICI) significantly improves the OS of patients with EGFR/ALK-negative advanced NSCLC
.

PS≥1, bone metastasis and liver metastasis are poor prognostic factors

In summary, studies have shown that the approval of Immune Checkpoint Inhibitors (ICI) significantly improves the OS of patients with EGFR/ALK-negative advanced NSCLC

Original source:

Mouritzen, MT; Carus, A.

Mouritzen, MT; Carus, A.
; Ladekarl, M.
; et al.
Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy.
Cancers 2021, 13, 4846.
https://doi.
org/ 10.
3390/cancers13194846 https://doi.
org/ leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.